Changes

Jump to: navigation, search

Chronic myelomonocytic leukemia

512 bytes removed, 07:16, 8 August 2018
m
no edit summary
<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''-->
 
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].
{| class="wikitable" style="text-align:center; width:50%;"
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor'''
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup(C)
|[[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup(C)
|[[#Azacitidine_.26_Lenalidomide|Azacitidine & Lenalidomide]]
|style="background-color:#ffffbf"|Seems not superior
===References===
# Drummond MW, Pocock C, Boissinot M, Mills J, Brown J, Cauchy P, Cross NC, Hartley S, Kell J, Szubert A, Cockerill PN, Bowen DT. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia. 2014 Jul;28(7):1570-2. Epub 2014 Feb 26. [https://www.nature.com/leu/journal/v28/n7/full/leu201485a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24569776 PubMed]
# '''SWOG S1117:''' Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28486043 PubMed]
==Azacitidine & Lenalidomide {{#subobject:92571f|Regimen=1}}==
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup(E)
|[[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup(E)
|[[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
===References===
# '''SWOG S1117:''' Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28486043 PubMed]
==Azacitidine & Vorinostat {{#subobject:a816bd|Regimen=1}}==
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup(E)
|[[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 Sekeres et al. 2017 (SWOG S1117)]
|rowspan=2 style="background-color:#91cf61"|Randomized Phase II, <20 pts in subgroup(E)
|[[#Azacitidine_monotherapy|Azacitidine]]
|style="background-color:#ffffbf"|Seems not superior
===References===
# '''SWOG S1117:''' Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. [http://ascopubs.org/doi/full/10.1200/JCO.2015.66.2510 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28486043 PubMed]
==Decitabine monotherapy {{#subobject:c9cd47|Regimen=1}}==
LookupUsers, editors, emailconfirmed
24,702
edits

Navigation menu